Edward T. Richardson Source Confirmed

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

Researcher

John Brown University

faculty

17 h-index 125 pubs 1,406 cited

Research Areas

Links

ORCID

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Dr. Edward T. Richardson's research centers on cancer immunotherapy and the identification of relevant biomarkers, with a particular emphasis on advanced breast cancer therapies. His work explores the interplay between cancer cells and the immune system, including mechanisms by which quiescent cancer cells resist T cell-mediated attack through the formation of immunosuppressive niches. Richardson's investigations extend to the clinical application of immune checkpoint inhibitors, such as nivolumab and pembrolizumab, often in combination with other targeted therapies for metastatic breast cancer. His research incorporates advanced biosensing and bioanalysis techniques to profile the molecular characteristics of tumors and predict patient response to immunotherapy. He is affiliated with John Brown University.

Metrics

h-index: 17
Publications: 125
Citations: 1,406

Selected Publications

Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies (2024) DOI
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer (2024) DOI
885 Characterization of the tumor microenvironment in advanced breast cancer patients treated with talazoparib followed by combination of talazoparib and avelumab (2023) DOI
Figure 4 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer (2023) DOI
Figure 3 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer (2023) DOI
Figure 3 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer (2023) DOI
Supplementary Fig. S5 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer (2023) DOI
Supplementary Fig. S3 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer (2023) DOI
Supplementary Fig. S1 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer (2023) DOI
Supplementary Fig. S2 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer (2023) DOI
Figure 7 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer (2023) DOI
Supplementary Tables S2-13 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer (2023) DOI
Supplementary Fig. S6 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer (2023) DOI
Supplementary Table S1 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer (2023) DOI
Figure 5 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer (2023) DOI